CA2957462C - Cd3 binding domain - Google Patents

Cd3 binding domain Download PDF

Info

Publication number
CA2957462C
CA2957462C CA2957462A CA2957462A CA2957462C CA 2957462 C CA2957462 C CA 2957462C CA 2957462 A CA2957462 A CA 2957462A CA 2957462 A CA2957462 A CA 2957462A CA 2957462 C CA2957462 C CA 2957462C
Authority
CA
Canada
Prior art keywords
seq
antigen binding
binding protein
depicted
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2957462A
Other languages
English (en)
French (fr)
Other versions
CA2957462A1 (en
Inventor
Eugene Zhukovsky
Melvyn Little
Stefan Knackmuss
Uwe Reusch
Kristina Ellwanger
Ivica FUCEK
Michael WEICHEL
Markus ESER
Fionnuala McAleese-Eser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/002177 external-priority patent/WO2015018527A1/en
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of CA2957462A1 publication Critical patent/CA2957462A1/en
Application granted granted Critical
Publication of CA2957462C publication Critical patent/CA2957462C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Gyroscopes (AREA)
  • Optical Communication System (AREA)
CA2957462A 2014-08-07 2015-08-05 Cd3 binding domain Active CA2957462C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2014/002177 2014-08-07
PCT/EP2014/002177 WO2015018527A1 (en) 2013-08-07 2014-08-07 ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII
EP15154772.6A EP2982693A1 (en) 2014-08-07 2015-02-11 CD3 binding domain
EP15154772.6 2015-02-11
PCT/EP2015/068070 WO2016020444A1 (en) 2014-08-07 2015-08-05 Cd3 binding domain

Publications (2)

Publication Number Publication Date
CA2957462A1 CA2957462A1 (en) 2016-02-11
CA2957462C true CA2957462C (en) 2023-10-17

Family

ID=52468915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2957462A Active CA2957462C (en) 2014-08-07 2015-08-05 Cd3 binding domain

Country Status (14)

Country Link
US (1) US10066015B2 (show.php)
EP (2) EP2982693A1 (show.php)
JP (1) JP6669722B2 (show.php)
CN (1) CN107001468B (show.php)
AU (1) AU2015299039B2 (show.php)
BR (1) BR112017002422B1 (show.php)
CA (1) CA2957462C (show.php)
DK (1) DK3177646T3 (show.php)
HR (1) HRP20202024T1 (show.php)
HU (1) HUE051919T2 (show.php)
LT (1) LT3177646T (show.php)
RU (1) RU2742691C2 (show.php)
SI (1) SI3177646T1 (show.php)
WO (1) WO2016020444A1 (show.php)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493563B2 (en) 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
PL3387015T3 (pl) 2015-12-09 2022-02-14 F. Hoffmann-La Roche Ag Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
CA3013558C (en) 2016-02-05 2024-11-12 Universiteit Gent CD8 LIAISON OFFICERS
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
EP3586872A4 (en) 2017-02-24 2020-12-30 Chugai Seiyaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION, ANTIGEN BINDING MOLECULES, METHOD OF TREATMENT AND METHOD OF SCREENING
EP3366704A1 (en) 2017-02-28 2018-08-29 Affimed GmbH Antibodies specific for mmp1/hla-a2 complex
EP3619235A1 (en) 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
EP3634998B8 (en) * 2017-06-05 2025-04-09 Numab Therapeutics AG Anti-cd3 epsilon antibodies
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
KR101973060B1 (ko) 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
US20200399373A1 (en) * 2018-02-14 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule and combination
EP3765520A1 (en) 2018-03-14 2021-01-20 NovImmune SA Anti-cd3 epsilon antibodies and methods of use thereof
SG11202009804RA (en) 2018-04-11 2020-11-27 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
TW202035451A (zh) * 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
CN112888482B (zh) 2018-08-23 2024-06-25 里珍纳龙药品有限公司 抗Fcε-R1α(FCER1A)抗体，结合FCER1A和CD3的双特异性抗原结合分子及其用途
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
KR102899856B1 (ko) * 2019-03-29 2025-12-15 주식회사 녹십자 항-메소텔린 항체, 항-cd3 항체 또는 항-egfr 항체를 포함하는 융합 단백질 및 이를 포함하는 이중 특이적 또는 삼중 특이적 항체 및 이의 용도
BR112022014667A2 (pt) 2020-01-29 2022-09-20 Inhibrx Inc Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
TWI888487B (zh) * 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
MX2022014938A (es) 2020-05-27 2023-03-06 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas.
CN116261590B (zh) * 2020-09-29 2025-10-17 信达生物制药(苏州)有限公司 抗cd3抗体以及其用途
KR20240005691A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
KR20240005722A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약
AR126161A1 (es) 2021-06-17 2023-09-27 Boehringer Lngelheim Int Gmbh Moléculas de fijación triespecíficas novedosas
WO2023125729A1 (zh) * 2021-12-31 2023-07-06 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
JP2025503573A (ja) 2021-12-31 2025-02-04 キィノ バイオテクノロジー カンパニー リミテッド 抗ｇｐｒｃ５ｄ抗体及びその応用
AU2023238766A1 (en) 2022-03-23 2024-07-25 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP7701982B2 (ja) 2022-04-13 2025-07-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の薬学的組成物及び使用方法
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024152963A1 (zh) * 2023-01-18 2024-07-25 贝达药业股份有限公司 抗cd3的人源化抗体及其应用
WO2025224084A1 (en) 2024-04-22 2025-10-30 Engimmune Therapeutics Ag Proteins comprising t cell receptor constant domains

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1297090B1 (it) * 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
CN101575377B (zh) * 1999-03-09 2012-12-26 津莫吉尼蒂克斯公司 作为zalpha受体之配体的人细胞因子及其用途
ES2276735T3 (es) 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
SI1716178T1 (sl) 2004-02-16 2010-11-30 Micromet Ag Manj imunogene vezne molekule
EP2612868B1 (en) * 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
EP2698431B1 (en) * 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
NZ703939A (en) * 2011-05-21 2016-01-29 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
WO2014106004A2 (en) * 2012-12-28 2014-07-03 Abbvie, Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
DK3030581T3 (da) * 2013-08-07 2021-04-12 Affimed Gmbh Antistofbindingssteder, der er specifikke for egfrviii
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins

Also Published As

Publication number Publication date
RU2017105120A (ru) 2018-09-10
BR112017002422B1 (pt) 2024-02-20
CA2957462A1 (en) 2016-02-11
CN107001468B (zh) 2021-04-09
HUE051919T2 (hu) 2021-04-28
RU2742691C2 (ru) 2021-02-09
US20160039934A1 (en) 2016-02-11
SI3177646T1 (sl) 2021-04-30
EP3177646B1 (en) 2020-10-07
LT3177646T (lt) 2021-01-11
RU2017105120A3 (show.php) 2019-02-20
AU2015299039A1 (en) 2017-03-02
HRP20202024T1 (hr) 2021-02-19
EP2982693A1 (en) 2016-02-10
DK3177646T3 (da) 2020-12-07
EP3177646A1 (en) 2017-06-14
WO2016020444A1 (en) 2016-02-11
JP2017529067A (ja) 2017-10-05
JP6669722B2 (ja) 2020-03-18
US10066015B2 (en) 2018-09-04
CN107001468A (zh) 2017-08-01
BR112017002422A2 (pt) 2017-11-28
AU2015299039B2 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CA2957462C (en) Cd3 binding domain
AU2011373925B2 (en) Multivalent antigen-binding Fv molecule
US20180346590A1 (en) Antigen-binding molecule and uses thereof
EP2371866B1 (en) Multivalent antigen-binding Fv molecule
US20220073620A1 (en) Antibody fusion protein, preparation method therefor and application thereof
JP2023547662A (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
HK1240236B (zh) Cd3结合结构域
HK1240236A1 (en) Cd3 binding domain
TW202413430A (zh) 抗ｃｄ３７和ｃｄ３的雙特異性抗體
WO2024188319A1 (zh) 抗muc17、cd3和cd28三特异性抗体
TW202546011A (zh) 多特異性抗體及其用途
CN118894943A (zh) 靶向密蛋白的双特异性抗体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200615

EEER Examination request

Effective date: 20200615

EEER Examination request

Effective date: 20200615

EEER Examination request

Effective date: 20200615

EEER Examination request

Effective date: 20200615

EEER Examination request

Effective date: 20200615

EEER Examination request

Effective date: 20200615